$1.94 Billion in Sales Expected for Quest Diagnostics Inc (NYSE:DGX) This Quarter

Analysts expect that Quest Diagnostics Inc (NYSE:DGX) will post $1.94 billion in sales for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Quest Diagnostics’ earnings, with the lowest sales estimate coming in at $1.94 billion and the highest estimate coming in at $1.95 billion. Quest Diagnostics reported sales of $1.89 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 2.6%. The company is scheduled to report its next quarterly earnings results on Tuesday, October 22nd.

According to Zacks, analysts expect that Quest Diagnostics will report full-year sales of $7.71 billion for the current year, with estimates ranging from $7.66 billion to $7.75 billion. For the next year, analysts expect that the company will report sales of $7.92 billion, with estimates ranging from $7.82 billion to $8.02 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Quest Diagnostics.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.69 by $0.04. The business had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.94 billion. Quest Diagnostics had a net margin of 9.64% and a return on equity of 15.05%. The business’s revenue was up 1.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.75 earnings per share.



DGX has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Quest Diagnostics from a “sell” rating to a “hold” rating and set a $111.00 price objective on the stock in a report on Wednesday, July 24th. Evercore ISI restated a “buy” rating and issued a $108.00 price objective on shares of Quest Diagnostics in a report on Thursday, August 8th. Credit Suisse Group upped their price objective on shares of Quest Diagnostics from $99.00 to $105.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Mizuho set a $110.00 price objective on shares of Quest Diagnostics and gave the stock a “buy” rating in a report on Monday, May 20th. Finally, Canaccord Genuity upped their price objective on shares of Quest Diagnostics from $108.00 to $112.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have assigned a buy rating to the company’s stock. Quest Diagnostics presently has a consensus rating of “Hold” and an average target price of $105.06.

DGX traded up $1.04 during midday trading on Monday, reaching $104.97. The company’s stock had a trading volume of 1,206,128 shares, compared to its average volume of 1,124,224. The firm has a market capitalization of $14.09 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 2.13 and a beta of 0.87. The company has a current ratio of 0.82, a quick ratio of 0.77 and a debt-to-equity ratio of 0.58. Quest Diagnostics has a 1 year low of $78.95 and a 1 year high of $109.05. The stock’s 50-day moving average is $101.69 and its 200-day moving average is $96.55.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Stockholders of record on Friday, October 4th will be paid a $0.53 dividend. The ex-dividend date is Thursday, October 3rd. This represents a $2.12 annualized dividend and a dividend yield of 2.02%. Quest Diagnostics’s dividend payout ratio is presently 33.60%.

Several hedge funds and other institutional investors have recently modified their holdings of DGX. Pearl River Capital LLC bought a new position in shares of Quest Diagnostics in the second quarter worth approximately $28,000. Wealthcare Advisory Partners LLC bought a new position in Quest Diagnostics during the second quarter valued at approximately $29,000. Berman Capital Advisors LLC lifted its position in Quest Diagnostics by 47.7% during the second quarter. Berman Capital Advisors LLC now owns 319 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 103 shares during the period. Penserra Capital Management LLC bought a new position in Quest Diagnostics during the first quarter valued at approximately $42,000. Finally, Signaturefd LLC lifted its position in Quest Diagnostics by 74.7% during the first quarter. Signaturefd LLC now owns 505 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 216 shares during the period. Hedge funds and other institutional investors own 89.73% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Recommended Story: Cost of Goods Sold (COGS)

Get a free copy of the Zacks research report on Quest Diagnostics (DGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.